Effect Of Recombinant Human Erythropoietin On IL-1β And TNF-α Dynamic Expression For SD Newborn Rats’s New Model Of Bronchial Pulmonary Dysplasia

Objective: Bronchial pulmonary dysplasia (BPD) is still one of themost intractable problems in neonatal intensive care unit (UICU), and in infantsit is the most common chronic respiratory disease. Due to advances in perinatalcare and the natural history of infants affected and neonatal respiratory therapythe clinical characteristics by BPD have widely changed in the last decades. Thesever presentation BPD transition from the classical to the new: The mainfeatures is alveoli and lung microvascular dysplasia. More and more evidencethat BPD results is favors pro-inflammatory mechanisms, from a persistentimbalance between anti-inflammatory and pro-inflammatory mechanisms. Dueto recombinant human erythropoietion (rhEPO) was demonstrated to haveanti-inflammatory, anti-oxidative, anti-apoptotic and Promote angiogenesisproperties. rhEPO was proved to have protective effect with inflammation lunginjury. So we hypothesized that the administration of rhEPO could help infantswith BPD. Because of postnatal lung development in Sprague-Dawley (SD)newborn rats is similar to human’s for the timing, the sequence, the immunoreaction and the physiopathologic mechanism. In the this study, weusing SD newborn rats to build SD newborn rats new BPD model. TO observethe effect of the rhEPO administration on interleukin-1β (IL-1β) and tumornecrosis factor-α (TNF-α) temporal expression with SD newborn rats new BPDmodel’s bronchoalveolar lavage fluid (BALF), explore influence of rhEPO onSD newborn rats new BPD model’s genesis and development. Indirectly providemore information for treatment and pathogenetic mechanism of clinic’s newBPD.Methods: Through SD pregnant rats on15th day for5ul/gestation sacinjection standard is30ng/ml lipopolysaccharide (LPS), then SD newborn ratsinhalation60%oxygen concentrations builded SD newborn rats new BPDmodel. After rhEPO (1200IU/kg) intervention SD newborn rats new BPD model,through administrated subcutaneously, altogether of seven from the first daybegin and every other day at a time. BALF was collected at scheduled timepoints with born on the1th day, the7th day and14th day. The expression ofIL-1β and TNF-α proteins in the BALF were measured by enzyme linkedlmmunosorbent assay (ELISA). SD pregnant rats on15th day gestation sacinjection phosphate buffer saline (PBS), SD newborn rats inhalation air (21%oxygen) and SD newborn rats no rhEPO intervention is control group as contrastanalysis. This study includes five groups: experimental group Ⅰ (PBS+21%O2),experimental group Ⅱ (PBS+60%O2+rhEPO), experimental group Ⅲ(PBS+60%O2), experimental group Ⅳ (LPS+60%O2+rhEPO) and experimentalgroup Ⅴ (LPS+60%O2).Results: Before delivery with intraamniotic injection of LPS and afterdelivery with exposure of hyperoxia can increase SD newborn rats BALF’sIL-1β and TNF-α expression, statistical significant were observed born on1th day,7th day and14th day. After rhEPO intervention, the SD newborn ratsBALF’s IL-1β and TNF-α expression reduce.Conclusions: SD newborn rats new BPD model BALF’s IL-1β andTNF-α expression markedly increased, suggesting these cytokines play animportant role in development of SD newborn rats new BPD model. WhilerhEPO intervention can obviously reduce it expression, rhEPO may haveprotective effect with SD newborn rats new BPD model.